Cardima Reports Favorable Revelation Tx Preliminary Phase III Clinical Data.

Business Editors & Health/Medical Writers

FREMONT, Calif.--(BW HealthWire)--June 13, 2002

Six Month Follow-up Data Shows 97% of Patients Report Reduced

Atrial Fibrillation (AF) Episodes;

50% Report No Recurrence of AF Episodes

Cardima(R), Inc. (Nasdaq:CRDM) -- developer of the REVELATION(TM) Tx and REVELATION(TM) Helix(TM) microcatheter systems, today announced preliminary data from its REVELATION Tx Phase III clinical trial for the treatment of atrial fibrillation (AF). Preliminary Phase III data indicate that 97% of the patients had a greater than or equal to 50% reduction in their AF episodes, and 50% of the patients reported no recurrence of AF episodes. The data represents a compilation of results from six-month follow up of 45 patients who had previously failed two levels of anti-arrhythmic drug therapy and had documented episodes of AF in the 30-day baseline monitoring period. The patients were treated with the REVELATION Tx at 18 investigational sites in the U.S.

The Phase II study indicated that, at six-month follow up, 87% of the 37 patients had a greater than or equal to 50% reduction in their AF episodes, and 48% of the patients reported no recurrence of AF. Results of this study were reported in April 2001.

Cardima expects to complete the necessary six-month follow up of all patients enrolled in the REVELATION Tx Phase III study in June 2002 and plans to submit, in the third quarter of this year, a pre-market approval (PMA) application seeking U.S. Food and Drug Administration (FDA) approval of REVELATION Tx for the treatment of AF.

"Data collected from the Phase III study further supports our belief that the REVELATION Tx microcatheter system can be a vital tool in the treatment of AF," said Gabriel Vegh, Chief Executive Officer of Cardima. "We believe that the REVELATION Tx is the only device for treating AF currently in Phase III clinical trials and we are targeting FDA approval of the REVELATION Tx by the end of this year," continued Mr. Vegh.

"We are also encouraged by the continued confidence and positive experience physicians participating in the Phase III study are reporting after using the REVELATION Tx to treat their patients," added Mr. Vegh.

Cardima, Inc. developed the linear ablation REVELATION Tx and REVELATION Helix systems for treating AF. Since AF afflicts an estimated 2 million people in the United States and approximately 4.5 million people worldwide, the Company believes it is a potential $6 billion market that is poorly served by current treatment alternatives. The REVELATION Tx microcatheter system is a minimally invasive, single-use system with the potential of curing AF, and is believed by the Company to be at least two years ahead of other development-stage ablation therapies in the approval process. Phase I and II data with the REVELATION Tx microcatheter system have demonstrated safety and promising efficacy. The Company is targeting FDA approval for the REVELATION Tx by the end of calendar year 2002. The Company's REVELATION Helix received CE mark approval in December 2001 with initial market launch in the European Union in the first quarter of 2002.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to raise additional capital, conduct successful clinical trials, obtain regulatory approvals and gain acceptance from the marketplace for its products. Additional risks are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2001, Quarterly Reports on Form 10-Q and other reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.